apoptolidin

01/01/2022 - "The combination of cellular, structural, mutagenesis, and in vivo evidence defines the mechanism of action of apoptolidin family glycomacrolides and establishes a path to address oxidative phosphorylation-dependent cancers."
02/01/2015 - "We find the metabolic phenotype of the cell to be a critical determinant of apoptolidin sensitivity and the likely basis for cancer cell selectivity. "
01/30/2006 - "Apoptolidin is a natural product that selectively induces apoptosis in several cancer cell lines. "
07/07/2005 - "[reaction: see text] Apoptolidin (1) is a promising new therapeutic lead that exhibits remarkable selectivity against cancer cells relative to normal cells. "
02/16/2006 - "[structure: see text] Apoptolidin (1) exhibits potent and highly selective apoptosis inducing activity against sensitive cancer cell lines and is hypothesized to act by inhibition of mitochondrial F(0)F(1)-ATP synthase. "

01/01/2022 - "Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase."
12/19/2000 - "Nine different cell lines derived from human leukemias and melanomas, and colon, renal, central nervous system, and ovarian tumors are also sensitized to killing by apoptolidin."

10/01/2009 - "Biological evaluation of the new apoptolidin analogues was then conducted using growth inhibition assays based on the H292 human lung carcinoma cell line. "
02/15/2007 - "The isolation, characterization, and preliminary biological activity of apoptolidin D, a new apoptolidin that exhibits anti-proliferative activity against H292 human lung carcinoma cells at nanomolar concentrations, are reported. "

12/19/2000 - "Nine different cell lines derived from human leukemias and melanomas, and colon, renal, central nervous system, and ovarian tumors are also sensitized to killing by apoptolidin."

01/01/2001 - "PARP was completely cleaved in the presence of 1 microM apoptolidin within 6 h in a mouse lymphoma cell line. "